ReviewDiagnostics (Basel, Switzerland)2020
Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors.
Review in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Microbiome Changes after Type 2 Diabetes Treatment: A Systematic Review.Medicina (Kaunas, Lithuania) · 2021Pooled it
- Pooled it
- Short-Term Aerobic Exercise Did Not Change Telomere Length While It Reduced Testosterone Levels and Obesity Indexes in PCOS: A Randomized Controlled Clinical Trial Study.International journal of environmental research and public health · 2021Trial
- Exploring the Therapeutic Potential of SGLT-2 Inhibitors in Managing Metabolic Syndrome: A Narrative Review.Current drug research reviews · 2026Review
- Clinical and Genetic Factors Associated with Multivessel Coronary Artery Disease: A Cross-Sectional Study of CYP2C19 Polymorphisms and Metabolic Comorbidities.International journal of general medicine · 2026Article
- Integrating Renal and Metabolic Parameters into a Derived Risk Score for Hyperuricemia in Uncontrolled Type 2 Diabetes: A Retrospective Cross-Sectional Study in Northwest Romania.Medicina (Kaunas, Lithuania) · 2025Article
- Level of medication non-adherence among ambulatory patients with dyslipidemia and comorbid illness in Northwest Ethiopia: a multicenter cross-sectional study.Therapeutic advances in chronic disease · 2025Article
- Pre-diabetes and cardiovascular risk factors in NAFLD patients: a retrospective comparative analysis.Frontiers in endocrinology · 2025Article
- Lipid management strategies for diabetic patients align with an evidence-based guideline.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
- Higher Circulating Neutrophil Counts Is Associated with Increased Risk of All-Cause Mortality and Cardiovascular Disease in Patients with Diabetic Kidney Disease.Biomedicines · 2024Article
- Article
- Analysis of the Associations of Measurements of Body Composition and Inflammatory Factors with Cardiovascular Disease and Its Comorbidities in a Community-Based Study.Biomedicines · 2024Article
- To What Extent Does Cardiovascular Risk Classification of Patients with Type 2 Diabetes Differ between European Guidelines from 2023, 2021, and 2019? A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2024Article
- Educational Interventions for Individuals with Insulin-Treated Type 2 Diabetes Mellitus: A Systematic Review.Patient preference and adherence · 2024Review
- AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus.Acta diabetologica · 2023Article
- Investigating the relationship between lifestyle factors, family history, and diabetes mellitus in non-diabetic visitors to primary care centers.Saudi journal of biological sciences · 2023Article
- Sulfated Polysaccharide fromAntioxidants (Basel, Switzerland) · 2023Article
- Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus.Signal transduction and targeted therapy · 2023Article
- Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes.International journal of molecular sciences · 2023Article
- MicroRNAs as Biomarkers for Coronary Artery Disease Related to Type 2 Diabetes Mellitus-From Pathogenesis to Potential Clinical Application.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Reducing cardiovascular risk (CVR) is the main focus of diabetes mellitus (DM) management nowadays. Complex pathogenic mechanisms that are the subject of this review lead to early and severe atherosclerosis in DM patients. Although it is not a cardiovascular disease equivalent at the moment of diagnosis, DM subjects are affected by numerous cardiovascular complications, such as acute coronary syndrome, stroke, or peripheral artery disease, as the disease duration increases. Therefore, early therapeutic intervention is mandatory and recent guidelines focus on intensive CVR factor management: hyperglycaemia, hypertension, and dyslipidaemia. Most important, the appearance of oral or injectable antidiabetic medication such as SGLT-2 inhibitors or GLP-1 agonists has proven that an antidiabetic drug not only reduces glycaemia, but also reduces CVR by complex mechanisms. A profound understanding of intimate mechanisms that generate atherosclerosis in DM and ways to inhibit or delay them are of the utmost importance in a society where cardiovascular morbidity and mortality are predominant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.